The invention relates to particular crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile,its hydrates and solvates, its salts and hydrates and solvates of its salts, certainprocesses for their preparation, pharmaceutical compositions containingthese crystalline forms, and their use in diagnostic methods or, preferably,for the therapeutic treatment of warm-blooded animals, especially humans,and their use as an intermediate or for the preparation of pharmaceutical preparationsfor use in diagnostic methods or, preferably, for the therapeutic treatmentof warm-blooded animals, especially humans.
